US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Park Hotels & Resorts Inc.

10.83

+0.04000.37%

Post-market: 10.840.0100+0.09%19:21 EDT

Volume:2.47M

Turnover:26.72M

Market Cap:2.16B

PE:17.78

High:10.95

Open:10.90

Low:10.73

Close:10.79

Loading ...

Overview Company News Filings

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

Park Hotels & Resorts Inc : Bofa Global Research Cuts to Underperform From Neutral; Cuts Price Objective to $11 From $11.50

THOMSON REUTERS

CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

BofA Securities Downgrades Park Hotels & Resorts to Underperform From Neutral

MT Newswires Live

Larimar Therapeutics Reports First Quarter 2025 Financial Results

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD

Easterly Government Properties (DEA) Lags Q1 FFO and Revenue Estimates

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML

Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PK/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PK\",,,,,undefined,":{"symbol":"PK","market":"US","secType":"STK","nameCN":"Park Hotels & Resorts Inc.","latestPrice":10.83,"timestamp":1752091200000,"preClose":10.79,"halted":0,"volume":2467733,"hourTrading":{"tag":"盘后","latestPrice":10.84,"preClose":10.83,"latestTime":"19:21 EDT","volume":44384,"amount":480689.55,"timestamp":1752103275955},"delay":0,"floatShares":195610869,"shares":199892323,"eps":0.60926,"marketStatus":"Not Yet Opened","change":0.04,"latestTime":"07-09 16:00:00 EDT","open":10.9,"high":10.9491,"low":10.725,"amount":26723426.139620002,"amplitude":0.020769,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.60926,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1752134400000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":10.79,"dividendRate":0.129271,"preHourTrading":{"tag":"盘前","latestPrice":10.87,"preClose":10.79,"latestTime":"09:16 EDT","volume":1,"amount":10.87,"timestamp":1752066982019},"postHourTrading":{"tag":"盘后","latestPrice":10.84,"preClose":10.83,"latestTime":"19:21 EDT","volume":44384,"amount":480689.55,"timestamp":1752103275955},"volumeRatio":0.761521,"impliedVol":0.2116,"impliedVolPercentile":0.072},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PK\",,,,,undefined,":{"symbol":"PK","floatShares":195610869,"roa":"2.27%","roe":"3.90%","lyrEps":1.019323,"volumeRatio":0.761521,"shares":199892323,"dividePrice":1.4,"high":10.9491,"amplitude":0.020769,"preClose":10.79,"low":10.725,"week52Low":8.27,"pbRate":"0.62","psRate":"0.83","week52High":16.23,"institutionHeld":0,"latestPrice":10.83,"eps":0.60926,"divideRate":0.129271,"volume":2467733,"delay":0,"ttmEps":0.60926,"open":10.9,"prevYearClose":14.07,"prevWeekClose":10.84,"prevMonthClose":10.23,"prevQuarterClose":10.23,"fiveDayClose":10.65,"twentyDayClose":10.38,"sixtyDayClose":9.43,"earningDate":1753891200000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PK\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532018074","title":"Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2532018074","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532018074?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:00","pubTimestamp":1746100800,"startTime":"0","endTime":"0","summary":"Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025. CARLSBAD, Calif., May 01, 2025  -- Design Therapeutics, Inc. , a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced favorable data from a Phase 1 single- and multiple-ascending dose  trial of DT-168 in healthy volunteers, which will be presented on May 2, 2025 at Eyecelerator @ Park City 2025, an event backed by the American Academy of Ophthalmology highlighting industry advancements and innovative new products disrupting eye care.Based on these findings, Design plans to conduct a Phase 2 biomarker trial of DT-168 to evaluate safety, tolerability, and corneal endothelium biomarkers in patients with FECD. The trial will enroll FECD patients with the TCF4 mutation who are sc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/design-therapeutics-announces-favorable-phase-120000674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","DSGN","BK4181","LENZ","PK","BK4539","BK4007","BK4505","BK4218"],"gpt_icon":0},{"id":"2532020582","title":"Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2532020582","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532020582?lang=en_us&edition=fundamental","pubTime":"2025-05-01 18:30","pubTimestamp":1746095400,"startTime":"0","endTime":"0","summary":"– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND  in Thalassemia,with PDUFA Goal Date ofSeptember 7, 2025 –。– Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 –。– Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes  and Sickle Cell Disease –。– PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 –。ThePhase 3 RISE UP studyevaluating mitapivat for the treatment of sickle cell disease patients who are 16 years of age or older continued to progress as anticipated. This 52-week Phase 3 study completed enrollment in October 2024, enrolling more than 200 pat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agios-reports-first-quarter-2025-103000986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4139","AGIO","BK4181","BK4218"],"gpt_icon":0},{"id":"2531092058","title":"Park Hotels & Resorts Inc : Bofa Global Research Cuts to Underperform From Neutral; Cuts Price Objective to $11 From $11.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2531092058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531092058?lang=en_us&edition=fundamental","pubTime":"2025-04-30 21:44","pubTimestamp":1746020682,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R82ZO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PK","BK4181","BK4218"],"gpt_icon":0},{"id":"2531203126","title":"CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2531203126","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531203126?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:15","pubTimestamp":1746015300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April 30, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that TriStar Centennial Medical Center, through Sarah Cannon Research Institute , in Nashville, Tennessee, is a clinical trial site for the Company’s Phase 1 clinical of CER-1236. Collaborating with SCRI to advance cancer research, TriStar Centennial offers innovative clinical research trials for various disease indications. The trial is focused on patients with acute myeloid leukemia , and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-announces-121500799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4181","BK4161","CERO","CEROW","PK","CR","ORR","BK4218"],"gpt_icon":0},{"id":"2531368490","title":"BofA Securities Downgrades Park Hotels & Resorts to Underperform From Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2531368490","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531368490?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:39","pubTimestamp":1746013159,"startTime":"0","endTime":"0","summary":"Park Hotels & Resorts (PK) has an average rating of overweight and mean price target of $13.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PK"],"gpt_icon":0},{"id":"2531039139","title":"Larimar Therapeutics Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2531039139","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531039139?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:00","pubTimestamp":1746010800,"startTime":"0","endTime":"0","summary":"FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval. BLA seeking accelerated approval planned to be submitted by year-end 2025; global Phase 3 study planned to initiate in mid-2025. Completed dosing in adolescent PK run-in study; topline 50 mg dose data from the OLE study and data from adolescent cohort planned for program update in September 2025. Strong balance sheet of $157.5 million cash, cash equivalents and marketable securities as of March 31, 2025, with projected cash runway into second quarter of 2026. Potential for Accelerated Approval Pathway Based on Skin FXN Concentration","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/larimar-therapeutics-reports-first-quarter-110000276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LRMR","BK4181","BK4007","BK4218","BK4139","PK","LENZ"],"gpt_icon":0},{"id":"2531759499","title":"Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531759499","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531759499?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:00","pubTimestamp":1745935200,"startTime":"0","endTime":"0","summary":"An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer  who received AFM24 at 480 mg weekly demonstrates that higher drug exposure  leads to improved objective response rate  and longer progression free survival   without a negative impact on safety. These findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24. MANNHEIM, Germany, April 29, 2025  -- Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an exposure-outcome analysis of its innate cell engager  AFM24, in patients with advanced or metastatic non-small cell lung cancer  in a poster session at the 2025 Annual Meeting of the American Association for Cancer Research .The analysis is based on post-hoc exposure-response data from 72 NSCLC patients treated with 480 mg of AFM24 monotherapy or a combination of AFM24 with atezolizumab. F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/affimed-shows-higher-exposure-afm24-140000007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4195","BK4218","PK","PFS","BK4181","BK4139","ORR","OS","BK4211","BK4097","AFMD"],"gpt_icon":0},{"id":"2531733589","title":"Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2531733589","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531733589?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928000,"startTime":"0","endTime":"0","summary":"Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food. CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD. The trial demonstrated that 50mg CTx-1301 can be taken with or without food. Multiple pharmacokinetic  measurements were taken, and adverse events were consistent with previous findings and indicate a favorable tolerability profile.“Similar to the 25mg fasted versus fed study conducted with CTx-1301 , the 50mg dose of CTx-1301 demonstrated that it may also be taken with or without food, however patients should be advised to take the medication consistently as such,\" said Raul Silva, MD, Chief Science Officer, Cingulate. “Most importantly is that the unique formulation of CTx-1301 is bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cingulate-announces-positive-top-line-120000878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","US2Y.BOND","BK4139","US3Y.BOND","US5Y.BOND","BK4104","US12M.BOND","IE00BYQQ9H92.USD","IE00BFXG0V08.USD","BK4218","ABVC","CING","US6M.BOND","PK","BK4181","ADHD","US30Y.BOND","BK4007","BK4567","BK4588","IE00B5TLWC47.USD","FAST","US7Y.BOND","US10Y.BOND","CINGW"],"gpt_icon":0},{"id":"2531756622","title":"Easterly Government Properties (DEA) Lags Q1 FFO and Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2531756622","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531756622?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:45","pubTimestamp":1745927103,"startTime":"0","endTime":"0","summary":"Easterly Government Properties  came out with quarterly funds from operations  of $0.73 per share, missing the Zacks Consensus Estimate of $7.33 per share. This compares to FFO of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an FFO surprise of -90.04%. A quarter ago, it was expected that this property management company would post FFO of $0.30 per share when it actually produced FFO of $0.29, delivering a surprise of -3.33%.Easterly Government Properties , which belongs to the Zacks REIT and Equity Trust - Other industry, posted revenues of $78.68 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 3.83%. This compares to year-ago revenues of $72.8 million. The company has topped consensus revenue estimates just once over the last four quarters.Easterly Government Properties shares have lost about 92.6% since the beginning of the year versus the S&P 500's decline of -6%.While Easterly Gover","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/easterly-government-properties-dea-lags-114503468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","DEA"],"gpt_icon":0},{"id":"2531314781","title":"Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2531314781","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531314781?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:02","pubTimestamp":1745924520,"startTime":"0","endTime":"0","summary":"MIAMI, April 29, 2025  -- Pasithea Therapeutics Corp.  , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1  and other MAPK pathway driven cancer indications, today announced the Company has completed enrollment and initial dosing of three subjects in Cohort 6 with 30 mg capsules of PAS-004.The ongoing Phase 1 clinical trial is a multi-center, open-label, dose escalation 3+3 study design to evaluate the safety, tolerability, pharmacokinetics , pharmacodynamics , and preliminary efficacy of PAS-004 in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-announces-completion-enrollment-110200697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KTTAW","IE00B7SZL793.SGD","IE00B66KJ199.SGD","CNS","IE00B19Z4B17.USD","BK4181","BK4135","BK4007","BK4157","BK4023","LENZ","PD","LU1169590202.USD","PK","LU1169589451.USD","KTTA","AEIS","IE0031619046.USD","BK4139","BK4218"],"gpt_icon":0},{"id":"2531875364","title":"Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2531875364","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531875364?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April 29, 2025  -- Seres Therapeutics, Inc., a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week  Conference being held May 3-6, 2025, in San Diego, CA.Seres previously reported exploratory translational biomarker data from its SER-155 Phase 1b study, which provided evidence supporting the intended therapeutic mechanisms. These included promoting intestinal epithelial barrier integrity to reduce the translocation of bacteria and inflammatory bacterial products into the bloodstream, as well as modulating systemic inflammatory responses. New results presented at the DDW conference could help identify candidate biomarkers to support the further clinical development of live biotherapeutics to treat inflammatory and immune diseases, including ulcerative colitis and Crohn’s disease.Presentation Details - New ResearchTitle: Characterization of IBD microbiomes in Models of Microbiome Di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/seres-therapeutics-presents-data-2025-110000306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","LU1169589451.USD","MCRB","BK4139","BK4023","BK4218","LU1169590202.USD","PD","BK4181"],"gpt_icon":0},{"id":"2530409113","title":"Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2530409113","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530409113?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Significant Improvements in Multiple Inflammatory and Fibrotic Biomarkers. Further Confirms the Clinical Potential of Nebokitug As a First-in-Class Novel Treatment for PSC and Other Fibro-Inflammatory Conditions. Second EASL 2025 Poster Reports that Pharmacokinetic and Pharmacodynamic Data from the Phase 2 Spring Trial Demonstrates Effective and Dose-Dependent Antibody-Target Engagement. The second abstract presents an analysis of the pharmacodynamics and pharmacokinetics  of nebokitug and CCL24 using patient data from the Phase 2 SPRING trial in patients with PSC.2 PK analyses indicated dose-proportional increases in the concentration of nebokitug with steady-state","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-reports-positive-clinical-data-120000897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","BK4139","CMMB","PSC","PK","BK4218"],"gpt_icon":0},{"id":"2530365288","title":"Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2530365288","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530365288?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:00","pubTimestamp":1745838000,"startTime":"0","endTime":"0","summary":"Data presented at the American Association for Cancer Research  Annual Meeting 2025. Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose  identified. 5 of 7 best overall response evaluable patients achieved ORR  across all dose cohorts, including 1 CR and 1 CRh in 3 patients in preliminary RP2D cohort. 4 of 4 cCR patients were measurable residual disease  negative as assessed by local standard of care. Early deep responses with SENTI-202 noted across dose levels with all cCRs ongoing as of the data cut and longest durability of 8+ months. Company to host webcast to discuss the new Phase 1 SENTI-202 data today, April 28th at 8:30 AM ET; Register Here. Announces certain preliminary first quarter 2025 financial results and provides pipeline update. The Phase 1 study evaluated two dose levels  and two schedules  of SENTI-202 administered every 28 days on Days 0,7,14 or Days 0,3,7,10,14, respective","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/senti-bio-senti-202-first-110000851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4022","BK4181","BK4017","BK4139","SNTI","CAR","PK","OR","BK4230","BK4218"],"gpt_icon":0},{"id":"2530846508","title":"Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA","url":"https://stock-news.laohu8.com/highlight/detail?id=2530846508","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530846508?lang=en_us&edition=fundamental","pubTime":"2025-04-28 05:25","pubTimestamp":1745789110,"startTime":"0","endTime":"0","summary":"Y-mAbs Therapeutics (YMAB) announced the presentation of preclinical and translational pharmacokinetics, PK, data of CD38-SADA in a poster at the 2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/y-mabs-therapeutics-announces-presentation-of-pk-data-of-cd38-sada?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/y-mabs-therapeutics-announces-presentation-of-pk-data-of-cd38-sada?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["YMAB","BK4181","PK","BK4139","LENZ","BK4007","BK4218"],"gpt_icon":0},{"id":"2530450252","title":"Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530450252","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530450252?lang=en_us&edition=fundamental","pubTime":"2025-04-28 03:00","pubTimestamp":1745780400,"startTime":"0","endTime":"0","summary":"NEW YORK, April 27, 2025  -- Y-mAbs Therapeutics, Inc.  , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics  data of CD38-SADA in a poster at the 2025 American Association of Cancer Research  Annual Meeting being held on April 25-30, 2025 in Chicago, IL.The poster titled “Preclinical and translational pharmacokinetic  modeling of the self-assembling and disassembling  bispecific fusion protein CD38-SADA for first-in-human  pretargeted radioimmunotherapy ” characterizes the plasma concentrations of CD38-SADA in animal models over time and a range of doses. Utilizing in vitro binding kinetic parameters and PK data generated from three studies in mice, the study characterized the concentration- and time-dependent equilibrium between CD38-SADA tetramers and monomers.Res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/y-mabs-presents-translational-pharmacokinetics-190000483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4117","BK4107","BK4181","PK","YMAB","AFG","BK4218"],"gpt_icon":0},{"id":"2530616358","title":"Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530616358","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530616358?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:00","pubTimestamp":1745600400,"startTime":"0","endTime":"0","summary":"BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events. BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines. BDC-3042 showed signs of anti-tumor activity, including an unconfirmed partial response, stable disease ≥ 12 weeks in 3/3 non-small cell lung cancer patients and in 2/3 patients at the highest dose. Bolt is running a partnering process to advance development of BDC-3042. REDWOOD CITY, Calif., April 25, 2025  -- Bolt Biotherapeutics , a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced results from its Phase 1 dose-escalation clinical study of BDC-3042 at the American Association for Cancer Research  Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.“We are excited about the potential of BDC-3042 to help patients with cancer. This initial dose-escalation study de","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bolt-biotherapeutics-presents-results-phase-170000479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4585","BK4181","BK4107","LU0266512127.USD","LU0456854461.SGD","L","IHC","BK4162","BK4148","BOLT","BK4588","PK","BDC","CRC","BK4218","LU0053666078.USD","BK4213"],"gpt_icon":0},{"id":"2530168605","title":"Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530168605","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530168605?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:00","pubTimestamp":1745600400,"startTime":"0","endTime":"0","summary":"Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms. Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026. “The breadth of data shared at AACR highlights the strength of our oncology portfolio across antibody-drug conjugates and T cell engagers, and demonstrates the novel approaches we employ using each modality,” said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. “We’re particularly excited to share data on ZW209, the latest of our oncology nominated IND programs which has demonstrated promising anti-tumor activity in preclinical small cell lung cancer models by integrating CD28 co-stimulation into a trispecific T cell engager. We look forward to advancing ZW209 with an IND submission anticipated in the first half of 2026, while also progressing the differentiated programs in our wholly-owned pipeline.”","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zymeworks-presents-data-multiple-development-170000085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","PDX","PK","ZYME","BTC","TIL","BK4139","BK4505","CDX","BK4218"],"gpt_icon":0},{"id":"2530139432","title":"Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders","url":"https://stock-news.laohu8.com/highlight/detail?id=2530139432","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530139432?lang=en_us&edition=fundamental","pubTime":"2025-04-25 20:08","pubTimestamp":1745582880,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass. and BOULDER, Colo., April 25, 2025  -- Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from four pipeline programs during poster sessions at the American Association for Cancer Research  2025 Annual Meeting taking place in Chicago.“We welcome the opportunity to present updated results from these programs that represent our exciting pipeline of potential best-in-class targeted therapies,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “These data demonstrate Cogent’s ability to discover and advance novel therapies for rare disease populations with high unmet medical need, and we look forward to continuing to advance these candidates.”Title:The Reversible and Selective FGFR2/3 inhibitor CGT4859 has superior target coverage of resistanc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cogent-biosciences-presents-four-posters-120800118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","LU1854103824.USD","LU1854104046.USD","IE00BD6J9T35.USD","BK4107","LU2298322129.HKD","LU2360107325.USD","BK4181","BK4117","BK4089","BK4585","LU1861220033.SGD","BK4588","BK4505","LU0348723411.USD","BK4605","BK4139","LU1548497426.USD","BK4512","ON","LU2357305700.SGD","LU1861215975.USD","IE00BZ199S13.USD","LU0724618433.USD","PK","BK4218","LU1720051108.HKD","LU0124384867.USD","LU1978683503.SGD","COGT","AFG","BK4141","LU1670628061.USD","LU1720051017.SGD","LU1861219969.SGD","LU1670627923.USD","CCOI","LU1861214812.USD"],"gpt_icon":0},{"id":"2529818619","title":"CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2529818619","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529818619?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:15","pubTimestamp":1745496900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANSCISCO, Calif, April 24, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that Sarah Cannon Research Institute  at Colorado Blood Cancer Institute  in Denver, Colorado will be a key clinical trial site for the Company’s Phase 1 clinical trial of CER-1236. Partnering with SCRI to advance cancer research, CBCI is the region’s leader in blood cancer care and serves a seven-state region. The trial is focused on patients with acute myeloid leukemia , and patient enrollment is underway with first dosing of the initial cohort of patients expected by June.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and ad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-announces-121500646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CEROW","BK4161","CR","BK4181","CERO","ORR","PK","BK4139","BK4218"],"gpt_icon":0},{"id":"2529607368","title":"Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529607368","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529607368?lang=en_us&edition=fundamental","pubTime":"2025-04-24 19:02","pubTimestamp":1745492520,"startTime":"0","endTime":"0","summary":"Poster presentation on Monday, June 2, 2025 from 1:30 – 4:30 PM CDT at the ASCO Annual Meeting. MIAMI, April 24, 2025  -- Pasithea Therapeutics Corp.  , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1  and other MAPK pathway driven indications, today announced the acceptance of an abstract for a poster prenstation at the Annual Meeting of the American Society for Clinical Oncology  taking place May 30 – June 3, 2025, in Chicago, Illinois.The Company will present updated interim clinical data from its onging Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid tumors.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-present-updated-data-110200343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","IE00B19Z4B17.USD","IE00B66KJ199.SGD","BK4157","PK","BK4181","BK4139","BK4135","BK4218","LU1169590202.USD","KTTAW","KTTA","BK4007","LU1169589451.USD","BK4023","AEIS","IE00B7SZL793.SGD","PD","IE0031619046.USD","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PK\",params:#limit:5,,,undefined,":[{"date":"2025-07-31","symbol":"PK","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.55,"defaultRemindTime":1753992000000,"name":null,"time":"Post Market","dateTimestamp":1753934400000,"actualEps":null},{"date":"2025-06-30","symbol":"PK","amount":0.25,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-30","defaultRemindTime":1751290200000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-15","payableDate":"2025-06-30","currency":"USD","dateTimestamp":1751256000000,"payDate":"2025-07-15"},{"market":"US","date":"2025-05-05","symbol":"PK","fiscalQuarterEnding":"2025/03","expectedEps":0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746417600000,"reportTimeType":"pre","actualEps":0.46},{"date":"2025-03-31","symbol":"PK","amount":0.25,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-31","defaultRemindTime":1743427800000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-15","payableDate":"2025-03-31","currency":"USD","dateTimestamp":1743393600000,"payDate":"2025-04-15"},{"date":"2025-02-19","symbol":"PK","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":0.37,"defaultRemindTime":1739998800000,"name":null,"time":"Post Market","dateTimestamp":1739941200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PK\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-29","recordDate":"2017-03-31","paymentDate":"2017-04-17","value":0.43,"currency":"USD"},{"executeDate":"2017-06-28","recordDate":"2017-06-30","paymentDate":"2017-07-17","value":0.43,"currency":"USD"},{"executeDate":"2017-09-28","recordDate":"2017-09-29","paymentDate":"2017-10-16","value":0.43,"currency":"USD"},{"executeDate":"2017-12-28","recordDate":"2017-12-29","paymentDate":"2018-01-16","value":0.55,"currency":"USD"},{"executeDate":"2018-03-28","recordDate":"2018-03-30","paymentDate":"2018-04-16","value":0.43,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PK\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.125,"hold":0.625,"sell":0.125,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.625,"analysts":16,"updateTime":1751083200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PK\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PK","date":"2025-07-08","current":16.683926,"percent":0.837993,"low":-68.24471,"twenty":-10.162337,"median":-3.544901,"eighty":15.9278,"high":55.399897,"avg":-2.056846,"sd":27.437949,"marketCap":2118858623},"quantilePoints":[{"date":"2020-07-10","current":-4.756244,"twenty":10.682725,"median":14.429243,"eighty":31.344509,"marketCap":2273484522},{"date":"2020-07-17","current":-4.514735,"twenty":7.464564,"median":14.377186,"eighty":31.340758,"marketCap":2158043339},{"date":"2020-07-24","current":-4.204224,"twenty":6.899423,"median":14.324128,"eighty":31.317149,"marketCap":2009618961},{"date":"2020-07-31","current":-4.076076,"twenty":6.656099,"median":14.175607,"eighty":31.295818,"marketCap":1948364455},{"date":"2020-08-07","current":-2.566048,"twenty":6.428473,"median":14.137595,"eighty":31.259301,"marketCap":2101593620},{"date":"2020-08-14","current":-2.721392,"twenty":6.26364,"median":14.089266,"eighty":31.247128,"marketCap":2228820140},{"date":"2020-08-21","current":-2.525774,"twenty":6.153752,"median":14.006744,"eighty":31.247128,"marketCap":2068608967},{"date":"2020-08-28","current":-2.870982,"twenty":5.863333,"median":13.870814,"eighty":31.210909,"marketCap":2351334566},{"date":"2020-09-04","current":-3.046463,"twenty":5.667103,"median":13.801033,"eighty":31.128278,"marketCap":2495053412},{"date":"2020-09-11","current":-2.902626,"twenty":5.384533,"median":13.774657,"eighty":31.118835,"marketCap":2377251079},{"date":"2020-09-18","current":-3.095368,"twenty":4.792705,"median":13.714879,"eighty":31.059812,"marketCap":2535106206},{"date":"2020-09-25","current":-2.819201,"twenty":2.477694,"median":13.678818,"eighty":30.998429,"marketCap":2308925726},{"date":"2020-10-02","current":-3.046463,"twenty":2.452731,"median":13.647472,"eighty":30.967738,"marketCap":2495053412},{"date":"2020-10-09","current":-3.103998,"twenty":2.419945,"median":13.625211,"eighty":30.925242,"marketCap":2542174346},{"date":"2020-10-16","current":-2.865229,"twenty":2.407631,"median":13.604071,"eighty":30.830806,"marketCap":2346622473},{"date":"2020-10-23","current":-3.106875,"twenty":2.39881,"median":13.60157,"eighty":30.809558,"marketCap":2544530392},{"date":"2020-10-30","current":-2.856599,"twenty":2.384831,"median":13.570144,"eighty":30.743453,"marketCap":2339554333},{"date":"2020-11-06","current":-2.206192,"twenty":2.293797,"median":13.511461,"eighty":30.717484,"marketCap":2426811706},{"date":"2020-11-13","current":-3.043689,"twenty":2.260846,"median":13.488575,"eighty":30.70568,"marketCap":3348057703},{"date":"2020-11-20","current":-3.221469,"twenty":2.22504,"median":13.471041,"eighty":30.674988,"marketCap":3543616316},{"date":"2020-11-27","current":-3.581314,"twenty":2.209754,"median":13.450169,"eighty":30.667905,"marketCap":3939445798},{"date":"2020-12-04","current":-3.885469,"twenty":2.206595,"median":13.437336,"eighty":30.660823,"marketCap":4274015956},{"date":"2020-12-11","current":-3.77623,"twenty":2.197164,"median":13.4098,"eighty":30.634853,"marketCap":4153853434},{"date":"2020-12-18","current":-3.649856,"twenty":2.188516,"median":13.398907,"eighty":30.606523,"marketCap":4014841890},{"date":"2020-12-24","current":-3.681985,"twenty":2.181468,"median":13.390367,"eighty":30.587635,"marketCap":4050183808},{"date":"2020-12-31","current":-3.673418,"twenty":2.165633,"median":13.373288,"eighty":30.559305,"marketCap":4040759297},{"date":"2021-01-08","current":-3.726966,"twenty":2.127386,"median":13.357167,"eighty":30.487456,"marketCap":4099662493},{"date":"2021-01-15","current":-3.711972,"twenty":2.090996,"median":13.34366,"eighty":30.406499,"marketCap":4083169598},{"date":"2021-01-22","current":-3.889753,"twenty":2.071846,"median":13.334859,"eighty":30.325661,"marketCap":4278728211},{"date":"2021-01-29","current":-3.572747,"twenty":2.068781,"median":13.320798,"eighty":30.089882,"marketCap":3930021287},{"date":"2021-02-05","current":-3.887611,"twenty":2.05882,"median":13.314589,"eighty":29.899013,"marketCap":4276372084},{"date":"2021-02-12","current":-4.215327,"twenty":2.034301,"median":13.288201,"eighty":29.854103,"marketCap":4636859648},{"date":"2021-02-19","current":-4.444514,"twenty":2.013845,"median":13.280132,"eighty":29.737337,"marketCap":4888965330},{"date":"2021-02-26","current":-3.563311,"twenty":-2.231897,"median":13.271323,"eighty":29.699163,"marketCap":5131167540},{"date":"2021-03-05","current":-3.448497,"twenty":-2.455006,"median":13.256856,"eighty":29.625061,"marketCap":4965836198},{"date":"2021-03-12","current":-3.740659,"twenty":-2.561446,"median":13.245191,"eighty":29.508294,"marketCap":5386549593},{"date":"2021-03-19","current":-3.755425,"twenty":-2.654652,"median":13.226158,"eighty":29.474611,"marketCap":5407812650},{"date":"2021-03-26","current":-3.589648,"twenty":-2.723118,"median":13.200933,"eighty":29.409492,"marketCap":5169093647},{"date":"2021-04-01","current":-3.581442,"twenty":-2.747858,"median":13.188305,"eighty":29.387036,"marketCap":5157275875},{"date":"2021-04-09","current":-3.522353,"twenty":-2.785256,"median":13.150762,"eighty":29.281497,"marketCap":5072187914},{"date":"2021-04-16","current":-3.497732,"twenty":-2.84164,"median":13.078426,"eighty":29.200659,"marketCap":5036734596},{"date":"2021-04-23","current":-3.597855,"twenty":-2.856599,"median":13.071715,"eighty":29.043473,"marketCap":5180911420},{"date":"2021-04-30","current":-3.661868,"twenty":-2.86063,"median":13.065856,"eighty":28.92446,"marketCap":5273090044},{"date":"2021-05-07","current":-5.611001,"twenty":-2.872133,"median":13.00038,"eighty":27.600316,"marketCap":5285562943},{"date":"2021-05-14","current":-5.538196,"twenty":-2.918736,"median":12.98625,"eighty":26.702293,"marketCap":5216980694},{"date":"2021-05-21","current":-5.07124,"twenty":-2.973394,"median":12.984113,"eighty":26.504319,"marketCap":4777108342},{"date":"2021-05-28","current":-5.219361,"twenty":-3.010216,"median":12.953043,"eighty":26.370989,"marketCap":4916637744},{"date":"2021-06-04","current":-5.151577,"twenty":-3.032655,"median":12.935438,"eighty":26.342707,"marketCap":4852785306},{"date":"2021-06-11","current":-5.407649,"twenty":-3.066646,"median":12.921003,"eighty":26.23968,"marketCap":5094005628},{"date":"2021-06-18","current":-5.181703,"twenty":-3.103007,"median":12.910479,"eighty":26.122512,"marketCap":4881164167},{"date":"2021-06-25","current":-5.407649,"twenty":-3.130464,"median":12.883118,"eighty":26.110391,"marketCap":5094005628},{"date":"2021-07-02","current":-5.103877,"twenty":-3.201231,"median":12.837305,"eighty":26.041706,"marketCap":4807852108},{"date":"2021-07-09","current":-4.933162,"twenty":-3.220989,"median":12.808486,"eighty":25.863933,"marketCap":4647038560},{"date":"2021-07-16","current":-4.616837,"twenty":-3.39668,"median":12.795175,"eighty":25.55283,"marketCap":4349060515},{"date":"2021-07-23","current":-4.684621,"twenty":-3.442298,"median":12.778454,"eighty":25.461924,"marketCap":4412912953},{"date":"2021-07-30","current":-4.644453,"twenty":-3.472857,"median":12.762007,"eighty":25.27203,"marketCap":4375074472},{"date":"2021-08-06","current":-5.555659,"twenty":-3.499046,"median":12.754728,"eighty":25.175063,"marketCap":4438971639},{"date":"2021-08-13","current":-5.472783,"twenty":-3.515459,"median":12.739067,"eighty":25.092237,"marketCap":4372753628},{"date":"2021-08-20","current":-5.209355,"twenty":-3.540249,"median":12.712634,"eighty":25.013451,"marketCap":4162274952},{"date":"2021-08-27","current":-5.74509,"twenty":-3.546559,"median":12.705805,"eighty":24.987189,"marketCap":4590327091},{"date":"2021-09-03","current":-5.52902,"twenty":-3.565932,"median":12.702277,"eighty":24.944766,"marketCap":4417687278},{"date":"2021-09-10","current":-5.437265,"twenty":-3.571599,"median":12.695796,"eighty":24.807396,"marketCap":4344374481},{"date":"2021-09-17","current":-5.688853,"twenty":-3.581314,"median":12.675381,"eighty":24.746792,"marketCap":4545393441},{"date":"2021-09-24","current":-5.97004,"twenty":-3.589648,"median":12.636863,"eighty":24.72659,"marketCap":4770061692},{"date":"2021-10-01","current":-5.896043,"twenty":-3.599497,"median":12.622139,"eighty":24.665986,"marketCap":4710938468},{"date":"2021-10-08","current":-5.721411,"twenty":-3.607845,"median":12.595518,"eighty":24.655885,"marketCap":4571407660},{"date":"2021-10-15","current":-5.659254,"twenty":-3.625758,"median":12.578404,"eighty":24.655885,"marketCap":4521744152},{"date":"2021-10-22","current":-5.505341,"twenty":-3.649856,"median":12.569511,"eighty":24.645785,"marketCap":4398767847},{"date":"2021-10-29","current":-5.484622,"twenty":-3.670075,"median":12.545167,"eighty":24.625583,"marketCap":4382213344},{"date":"2021-11-05","current":-8.201051,"twenty":-3.681985,"median":12.518997,"eighty":24.605382,"marketCap":4994440260},{"date":"2021-11-12","current":-7.56811,"twenty":-3.701263,"median":12.505104,"eighty":24.575079,"marketCap":4608979198},{"date":"2021-11-19","current":-7.339009,"twenty":-3.720957,"median":12.481428,"eighty":24.44377,"marketCap":4469456483},{"date":"2021-11-26","current":-6.989532,"twenty":-3.729965,"median":12.465978,"eighty":24.427609,"marketCap":4256625222},{"date":"2021-12-03","current":-6.488616,"twenty":-3.750955,"median":12.411262,"eighty":24.415488,"marketCap":3951567081},{"date":"2021-12-10","current":-7.129323,"twenty":-3.770233,"median":12.390156,"eighty":24.397368,"marketCap":4341757726},{"date":"2021-12-17","current":-6.752665,"twenty":-3.792938,"median":12.369502,"eighty":24.247831,"marketCap":4112372922},{"date":"2021-12-23","current":-7.490449,"twenty":-3.83227,"median":12.348324,"eighty":24.162969,"marketCap":4561683362},{"date":"2021-12-31","current":-7.331243,"twenty":-3.873903,"median":12.336915,"eighty":24.124587,"marketCap":4464726899},{"date":"2022-01-07","current":-7.692369,"twenty":-3.888468,"median":12.314228,"eighty":24.072063,"marketCap":4684652535},{"date":"2022-01-14","current":-7.548695,"twenty":-3.917478,"median":12.283673,"eighty":24.03368,"marketCap":4597155239},{"date":"2022-01-21","current":-7.032246,"twenty":-3.996222,"median":12.241172,"eighty":24.02964,"marketCap":4282637931},{"date":"2022-01-28","current":-6.803145,"twenty":-4.087905,"median":12.214275,"eighty":24.013479,"marketCap":4143115216},{"date":"2022-02-04","current":-7.051662,"twenty":-4.210886,"median":12.177189,"eighty":23.964995,"marketCap":4294461890},{"date":"2022-02-11","current":-7.339009,"twenty":-4.305038,"median":12.115818,"eighty":23.924593,"marketCap":4469456483},{"date":"2022-02-18","current":-9.97933,"twenty":-4.379327,"median":12.077002,"eighty":23.906411,"marketCap":4580512556},{"date":"2022-02-25","current":-9.762948,"twenty":-4.434604,"median":12.034907,"eighty":23.88419,"marketCap":4481193234},{"date":"2022-03-04","current":-9.294121,"twenty":-4.477502,"median":11.989722,"eighty":23.857928,"marketCap":4266001369},{"date":"2022-03-11","current":-9.515655,"twenty":-4.530065,"median":11.874947,"eighty":23.585208,"marketCap":4367685437},{"date":"2022-03-18","current":-9.793479,"twenty":-4.62021,"median":11.802039,"eighty":23.304408,"marketCap":4495206674},{"date":"2022-03-25","current":-9.839796,"twenty":-4.668569,"median":11.613959,"eighty":23.136735,"marketCap":4516466191},{"date":"2022-04-01","current":-10.045649,"twenty":-4.723283,"median":11.244693,"eighty":22.801391,"marketCap":4610952931},{"date":"2022-04-08","current":-8.795089,"twenty":-4.748358,"median":11.177001,"eighty":22.577155,"marketCap":4036945983},{"date":"2022-04-14","current":-9.860381,"twenty":-4.774334,"median":11.132722,"eighty":22.280194,"marketCap":4525914865},{"date":"2022-04-22","current":-9.999332,"twenty":-4.831692,"median":11.002063,"eighty":21.938028,"marketCap":4589693414},{"date":"2022-04-29","current":-10.143429,"twenty":-4.933265,"median":10.846102,"eighty":20.988446,"marketCap":4655834133},{"date":"2022-05-06","current":-13.808923,"twenty":-5.010567,"median":10.72108,"eighty":20.329014,"marketCap":4501708843},{"date":"2022-05-13","current":-13.178967,"twenty":-5.093895,"median":7.386072,"eighty":20.146479,"marketCap":4296343172},{"date":"2022-05-20","current":-11.861786,"twenty":-5.147058,"median":6.828781,"eighty":19.994366,"marketCap":3866942225},{"date":"2022-05-27","current":-13.143174,"twenty":-5.175677,"median":6.45202,"eighty":19.781409,"marketCap":4284674668},{"date":"2022-06-03","current":-13.207601,"twenty":-5.20439,"median":6.373529,"eighty":19.661408,"marketCap":4305677976},{"date":"2022-06-10","current":-12.055068,"twenty":-5.217352,"median":6.1773,"eighty":18.57907,"marketCap":3929952147},{"date":"2022-06-17","current":-10.229627,"twenty":-5.287145,"median":5.839785,"eighty":18.013987,"marketCap":3334858443},{"date":"2022-06-24","current":-10.1652,"twenty":-5.323251,"median":5.651405,"eighty":17.603643,"marketCap":3313855136},{"date":"2022-07-01","current":-9.70705,"twenty":-5.360954,"median":5.101963,"eighty":17.208917,"marketCap":3164498284},{"date":"2022-07-08","current":-9.85738,"twenty":-5.388567,"median":3.861793,"eighty":17.068349,"marketCap":3213506001},{"date":"2022-07-15","current":-9.921808,"twenty":-5.409668,"median":2.45556,"eighty":16.809931,"marketCap":3234509308},{"date":"2022-07-22","current":-10.487336,"twenty":-5.439477,"median":2.417283,"eighty":16.594109,"marketCap":3418871672},{"date":"2022-07-29","current":-11.160244,"twenty":-5.472783,"median":2.404801,"eighty":15.354106,"marketCap":3638239547},{"date":"2022-08-05","current":-56.398031,"twenty":-5.505341,"median":2.387327,"eighty":15.148576,"marketCap":3383881882},{"date":"2022-08-12","current":-60.145409,"twenty":-5.52902,"median":2.299955,"eighty":15.006602,"marketCap":3608724532},{"date":"2022-08-19","current":-55.873399,"twenty":-5.552107,"median":2.257518,"eighty":14.887345,"marketCap":3352403911},{"date":"2022-08-26","current":-53.287708,"twenty":-5.563474,"median":2.212781,"eighty":14.845845,"marketCap":3197262483},{"date":"2022-09-02","current":-52.238442,"twenty":-5.614856,"median":2.207821,"eighty":14.818112,"marketCap":3134306541},{"date":"2022-09-09","current":-54.786659,"twenty":-5.644455,"median":2.197209,"eighty":14.800268,"marketCap":3287199543},{"date":"2022-09-16","current":-52.051073,"twenty":-5.663398,"median":2.187137,"eighty":14.752289,"marketCap":3123064408},{"date":"2022-09-23","current":-44.593792,"twenty":-5.688853,"median":2.168482,"eighty":14.705619,"marketCap":2675627535},{"date":"2022-09-30","current":-42.195471,"twenty":-5.714833,"median":2.125089,"eighty":14.651669,"marketCap":2531728239},{"date":"2022-10-07","current":-43.582,"twenty":-5.729107,"median":2.082185,"eighty":14.616649,"marketCap":2614920019},{"date":"2022-10-14","current":-44.219054,"twenty":-5.777649,"median":2.070313,"eighty":14.587307,"marketCap":2653143270},{"date":"2022-10-21","current":-47.216957,"twenty":-5.925642,"median":2.05882,"eighty":14.530184,"marketCap":2833017390},{"date":"2022-10-28","current":-48.828329,"twenty":-6.246611,"median":2.029326,"eighty":14.486979,"marketCap":2929699729},{"date":"2022-11-04","current":43.862859,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2675634425},{"date":"2022-11-11","current":47.03278,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2868999602},{"date":"2022-11-18","current":45.005505,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2745335826},{"date":"2022-11-25","current":45.742696,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2790304471},{"date":"2022-12-02","current":46.553606,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2839769982},{"date":"2022-12-09","current":45.41096,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2770068581},{"date":"2022-12-16","current":44.342034,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2704864044},{"date":"2022-12-23","current":42.941371,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2619423617},{"date":"2022-12-30","current":43.457404,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2650901669},{"date":"2023-01-06","current":44.010298,"twenty":-6.452657,"median":2.015912,"eighty":14.499284,"marketCap":2684628154},{"date":"2023-01-13","current":46.332449,"twenty":-6.452657,"median":2.015912,"eighty":14.544715,"marketCap":2826279388},{"date":"2023-01-20","current":47.585674,"twenty":-6.452657,"median":2.015912,"eighty":14.591155,"marketCap":2902726086},{"date":"2023-01-27","current":53.188324,"twenty":-6.452657,"median":2.015912,"eighty":14.629303,"marketCap":3244487794},{"date":"2023-02-03","current":54.478409,"twenty":-6.452657,"median":2.015912,"eighty":14.659241,"marketCap":3323182924},{"date":"2023-02-10","current":52.598572,"twenty":-6.452657,"median":2.015912,"eighty":14.710351,"marketCap":3208512877},{"date":"2023-02-17","current":50.681875,"twenty":-6.452657,"median":2.015912,"eighty":14.776825,"marketCap":3091594398},{"date":"2023-02-24","current":19.081678,"twenty":-6.452657,"median":2.015912,"eighty":14.800268,"marketCap":3091231855},{"date":"2023-03-03","current":19.2873,"twenty":-6.452657,"median":2.020509,"eighty":14.820409,"marketCap":3124542543},{"date":"2023-03-10","current":17.080295,"twenty":-6.452657,"median":2.020509,"eighty":14.858004,"marketCap":2767007824},{"date":"2023-03-17","current":15.80726,"twenty":-6.452657,"median":2.020509,"eighty":14.898703,"marketCap":2560776060},{"date":"2023-03-24","current":15.423721,"twenty":-6.452657,"median":2.034301,"eighty":15.020423,"marketCap":2498642845},{"date":"2023-03-31","current":16.930479,"twenty":-6.449731,"median":2.061884,"eighty":15.148576,"marketCap":2742737617},{"date":"2023-04-06","current":16.355172,"twenty":-6.449731,"median":2.08027,"eighty":15.339767,"marketCap":2649537795},{"date":"2023-04-14","current":16.231891,"twenty":-6.452657,"median":2.187137,"eighty":15.656584,"marketCap":2629566405},{"date":"2023-04-21","current":16.1771,"twenty":-6.452657,"median":2.20399,"eighty":16.160663,"marketCap":2620690231},{"date":"2023-04-28","current":15.916842,"twenty":-6.452657,"median":3.861793,"eighty":16.193538,"marketCap":2578528407},{"date":"2023-05-05","current":10.781494,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2716936387},{"date":"2023-05-12","current":11.431806,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2880815089},{"date":"2023-05-19","current":11.705622,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2949816648},{"date":"2023-05-26","current":11.13232,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2805344634},{"date":"2023-06-02","current":11.115206,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2801032037},{"date":"2023-06-09","current":12.184799,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":3070569377},{"date":"2023-06-16","current":11.243558,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2833376518},{"date":"2023-06-23","current":10.71304,"twenty":-6.455582,"median":4.787996,"eighty":16.201756,"marketCap":2699685997},{"date":"2023-06-30","current":10.926958,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2753593465},{"date":"2023-07-07","current":11.226444,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2829063920},{"date":"2023-07-14","current":11.799746,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2973535934},{"date":"2023-07-21","current":11.260671,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2837689115},{"date":"2023-07-28","current":10.76438,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2712623789},{"date":"2023-08-04","current":-57.485197,"twenty":-6.501042,"median":3.861793,"eighty":16.209975,"marketCap":2759289480},{"date":"2023-08-11","current":-60.090736,"twenty":-6.750335,"median":-2.450979,"eighty":16.209975,"marketCap":2884355344},{"date":"2023-08-18","current":-56.854736,"twenty":-6.930509,"median":-2.566048,"eighty":16.209975,"marketCap":2729027307},{"date":"2023-08-25","current":-56.854736,"twenty":-7.00324,"median":-2.678241,"eighty":16.209975,"marketCap":2729027307},{"date":"2023-08-31","current":-58.203069,"twenty":-7.047778,"median":-2.730022,"eighty":16.209975,"marketCap":2793747322},{"date":"2023-09-08","current":-56.225513,"twenty":-7.135536,"median":-2.76742,"eighty":16.220933,"marketCap":2698824633},{"date":"2023-09-13","current":-59.641292,"twenty":-7.238826,"median":-2.81236,"eighty":16.220933,"marketCap":2862782005},{"date":"2023-09-20","current":-56.49518,"twenty":-7.292412,"median":-2.856599,"eighty":16.226412,"marketCap":2711768636},{"date":"2023-09-29","current":-56.270458,"twenty":-7.33179,"median":-2.859478,"eighty":16.256547,"marketCap":2700981967},{"date":"2023-10-06","current":-54.068179,"twenty":-7.350658,"median":-2.872421,"eighty":16.256547,"marketCap":2595272609},{"date":"2023-10-13","current":-54.023235,"twenty":-7.41434,"median":-2.928517,"eighty":16.256547,"marketCap":2593115275},{"date":"2023-10-20","current":-52.944568,"twenty":-7.474917,"median":-3.004751,"eighty":16.256547,"marketCap":2541339263},{"date":"2023-10-23","current":-52.405235,"twenty":-7.491226,"median":-3.007627,"eighty":16.256547,"marketCap":2515451257},{"date":"2023-11-03","current":-48.333767,"twenty":-7.537046,"median":-3.046463,"eighty":16.355172,"marketCap":2706690937},{"date":"2023-11-10","current":-48.821216,"twenty":-7.614707,"median":-3.102759,"eighty":16.355172,"marketCap":2733988086},{"date":"2023-11-17","current":-52.758411,"twenty":-7.692369,"median":-3.147149,"eighty":16.355172,"marketCap":2954470996},{"date":"2023-11-24","current":-54.558271,"twenty":-8.07291,"median":-3.21274,"eighty":16.355172,"marketCap":3055263184},{"date":"2023-12-01","current":-55.60819,"twenty":-8.887723,"median":-3.353198,"eighty":16.355172,"marketCap":3114058626},{"date":"2023-12-08","current":-56.170646,"twenty":-9.20165,"median":-3.416563,"eighty":16.355172,"marketCap":3145556185},{"date":"2023-12-13","current":-57.820518,"twenty":-9.294121,"median":-3.460856,"eighty":16.355172,"marketCap":3237949024},{"date":"2023-12-22","current":-62.432661,"twenty":-9.507389,"median":-3.497732,"eighty":16.36339,"marketCap":3496229004},{"date":"2024-01-05","current":-59.020425,"twenty":-9.574387,"median":-3.519891,"eighty":16.393525,"marketCap":3305143815},{"date":"2024-01-12","current":-60.445315,"twenty":-9.664756,"median":-3.542049,"eighty":16.393525,"marketCap":3384937630},{"date":"2024-01-19","current":-59.99535,"twenty":-9.712777,"median":-3.553469,"eighty":16.401744,"marketCap":3359739584},{"date":"2024-01-26","current":-58.232986,"twenty":-9.763771,"median":-3.571596,"eighty":16.393525,"marketCap":3261047233},{"date":"2024-02-02","current":-66.888565,"twenty":-9.823019,"median":-3.581378,"eighty":16.393525,"marketCap":3210651139},{"date":"2024-02-09","current":-57.220565,"twenty":-9.869644,"median":-3.59147,"eighty":16.393525,"marketCap":3204351628},{"date":"2024-02-16","current":-57.220565,"twenty":-9.956321,"median":-3.604489,"eighty":16.393525,"marketCap":3204351628},{"date":"2024-02-23","current":-60.89528,"twenty":-10.043591,"median":-3.622011,"eighty":16.393525,"marketCap":3410135677},{"date":"2024-03-01","current":35.936019,"twenty":-10.056469,"median":-3.625758,"eighty":16.447807,"marketCap":3485793844},{"date":"2024-03-08","current":37.18843,"twenty":-10.056469,"median":-3.625758,"eighty":16.567212,"marketCap":3607277745},{"date":"2024-03-15","current":36.961243,"twenty":-10.056469,"median":-3.625758,"eighty":16.670221,"marketCap":3585240545},{"date":"2024-03-22","current":38.523902,"twenty":-10.056469,"median":-3.625758,"eighty":16.766106,"marketCap":3736818537},{"date":"2024-03-28","current":38.306866,"twenty":-10.056469,"median":-3.625758,"eighty":16.809931,"marketCap":3715766038},{"date":"2024-04-05","current":37.156575,"twenty":-10.059306,"median":-3.629041,"eighty":16.978896,"marketCap":3604187794},{"date":"2024-04-12","current":37.894498,"twenty":-10.059306,"median":-3.629041,"eighty":17.16064,"marketCap":3675766290},{"date":"2024-04-19","current":35.007918,"twenty":-10.059306,"median":-3.629041,"eighty":17.258612,"marketCap":3395768056},{"date":"2024-04-26","current":35.44199,"twenty":-10.056469,"median":-3.625758,"eighty":17.840762,"marketCap":3437873054},{"date":"2024-05-03","current":36.498796,"twenty":-10.056469,"median":-3.625758,"eighty":18.170174,"marketCap":3357889189},{"date":"2024-05-10","current":36.511207,"twenty":-10.056469,"median":-3.625758,"eighty":18.755351,"marketCap":3359031034},{"date":"2024-05-17","current":37.541304,"twenty":-10.056469,"median":-3.625758,"eighty":19.13678,"marketCap":3453799934},{"date":"2024-05-24","current":36.396752,"twenty":-10.056469,"median":-3.625758,"eighty":19.228198,"marketCap":3348501156},{"date":"2024-05-31","current":35.595565,"twenty":-10.056469,"median":-3.625758,"eighty":19.551549,"marketCap":3274792011},{"date":"2024-06-07","current":34.863052,"twenty":-10.056469,"median":-3.625758,"eighty":19.788169,"marketCap":3207400793},{"date":"2024-06-14","current":34.496795,"twenty":-10.059306,"median":-3.629041,"eighty":19.972394,"marketCap":3173705183},{"date":"2024-06-21","current":33.832955,"twenty":-10.062143,"median":-3.632324,"eighty":20.117746,"marketCap":3112631892},{"date":"2024-06-28","current":34.061866,"twenty":-10.071657,"median":-3.634664,"eighty":20.170141,"marketCap":3133691648},{"date":"2024-07-05","current":33.398026,"twenty":-10.071657,"median":-3.634664,"eighty":20.359437,"marketCap":3072618356},{"date":"2024-07-12","current":32.779968,"twenty":-10.071657,"median":-3.634664,"eighty":20.997672,"marketCap":3015757016},{"date":"2024-07-15","current":33.466699,"twenty":-10.071657,"median":-3.634664,"eighty":21.055774,"marketCap":3078936283},{"date":"2024-08-02","current":10.070358,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3081529526},{"date":"2024-08-09","current":9.455895,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2893503995},{"date":"2024-08-16","current":9.763127,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2987516760},{"date":"2024-08-23","current":10.179596,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3114956286},{"date":"2024-08-30","current":10.309316,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3154650565},{"date":"2024-09-06","current":9.742645,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2981249243},{"date":"2024-09-13","current":9.408104,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2878879787},{"date":"2024-09-20","current":10.718957,"twenty":-10.150883,"median":-3.673418,"eighty":21.101408,"marketCap":3280000919},{"date":"2024-09-27","current":10.084013,"twenty":-10.150883,"median":-3.673418,"eighty":20.560563,"marketCap":3085707871},{"date":"2024-10-04","current":9.585615,"twenty":-10.150883,"median":-3.673418,"eighty":20.205634,"marketCap":2933198274},{"date":"2024-10-11","current":9.756299,"twenty":-10.150883,"median":-3.673418,"eighty":20.146479,"marketCap":2985427588},{"date":"2024-10-18","current":9.626579,"twenty":-10.150883,"median":-3.673418,"eighty":20.146479,"marketCap":2945733309},{"date":"2024-10-25","current":9.462723,"twenty":-10.150883,"median":-3.673418,"eighty":20.138028,"marketCap":2895593168},{"date":"2024-10-31","current":8.714822,"twenty":-10.150883,"median":-3.673418,"eighty":19.647887,"marketCap":2902035670},{"date":"2024-11-08","current":9.117754,"twenty":-10.153746,"median":-3.674208,"eighty":19.166669,"marketCap":3036211945},{"date":"2024-11-15","current":9.111555,"twenty":-10.153746,"median":-3.674208,"eighty":18.78122,"marketCap":3034147899},{"date":"2024-11-22","current":9.099159,"twenty":-10.153746,"median":-3.674208,"eighty":16.930479,"marketCap":3030019806},{"date":"2024-11-29","current":9.638414,"twenty":-10.153746,"median":-3.674208,"eighty":16.766106,"marketCap":3209591825},{"date":"2024-12-06","current":9.756182,"twenty":-10.153746,"median":-3.674208,"eighty":16.574337,"marketCap":3248808703},{"date":"2024-12-13","current":9.53924,"twenty":-10.153746,"median":-3.674208,"eighty":16.377088,"marketCap":3176567086},{"date":"2024-12-20","current":8.968994,"twenty":-10.153746,"median":-3.674208,"eighty":16.1771,"marketCap":2986674836},{"date":"2024-12-27","current":9.334695,"twenty":-10.153746,"median":-3.674208,"eighty":15.960675,"marketCap":3108453562},{"date":"2025-01-03","current":8.541308,"twenty":-10.153746,"median":-3.674208,"eighty":15.74151,"marketCap":2844255649},{"date":"2025-01-10","current":8.398747,"twenty":-10.15661,"median":-3.674999,"eighty":15.187166,"marketCap":2796782587},{"date":"2025-01-17","current":8.429738,"twenty":-10.15661,"median":-3.674999,"eighty":14.123802,"marketCap":2807102818},{"date":"2025-01-24","current":8.541308,"twenty":-10.15661,"median":-3.674999,"eighty":12.229294,"marketCap":2844255649},{"date":"2025-01-31","current":8.355358,"twenty":-10.15661,"median":-3.674999,"eighty":11.774076,"marketCap":2782334264},{"date":"2025-02-07","current":8.175606,"twenty":-10.15661,"median":-3.674999,"eighty":11.669683,"marketCap":2722476924},{"date":"2025-02-14","current":7.915276,"twenty":-10.15661,"median":-3.674999,"eighty":11.541332,"marketCap":2635786984},{"date":"2025-02-21","current":12.449378,"twenty":-10.15661,"median":-3.674999,"eighty":11.52593,"marketCap":2639268117},{"date":"2025-02-28","current":11.712888,"twenty":-10.15661,"median":-3.674999,"eighty":11.52593,"marketCap":2483132177},{"date":"2025-03-07","current":11.32214,"twenty":-10.159473,"median":-3.675279,"eighty":11.440344,"marketCap":2400293756},{"date":"2025-03-14","current":10.388159,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2202289726},{"date":"2025-03-21","current":11.045758,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2341700727},{"date":"2025-03-28","current":10.62642,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2252800958},{"date":"2025-04-04","current":9.263569,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":1963876709},{"date":"2025-04-11","current":8.979147,"twenty":-10.15661,"median":-3.674999,"eighty":11.484858,"marketCap":1903579170},{"date":"2025-04-17","current":9.09341,"twenty":-10.15661,"median":-3.674999,"eighty":11.484858,"marketCap":1927802871},{"date":"2025-04-25","current":9.512373,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2016623108},{"date":"2025-05-02","current":9.559983,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2026716317},{"date":"2025-05-09","current":16.384875,"twenty":-10.159473,"median":-3.675279,"eighty":11.531064,"marketCap":2080879082},{"date":"2025-05-16","current":17.045936,"twenty":-10.159473,"median":-3.674208,"eighty":11.65257,"marketCap":2164833858},{"date":"2025-05-23","current":16.148781,"twenty":-10.159473,"median":-3.6534,"eighty":11.72393,"marketCap":2050895233},{"date":"2025-05-30","current":16.510791,"twenty":-10.159473,"median":-3.629041,"eighty":11.766258,"marketCap":2096870468},{"date":"2025-06-06","current":15.771032,"twenty":-10.159473,"median":-3.604398,"eighty":11.937378,"marketCap":2002921076},{"date":"2025-06-13","current":16.447833,"twenty":-10.159473,"median":-3.588007,"eighty":12.388042,"marketCap":2088874775},{"date":"2025-06-20","current":16.038604,"twenty":-10.162337,"median":-3.578159,"eighty":15.511387,"marketCap":2036902771},{"date":"2025-06-27","current":16.55801,"twenty":-10.162337,"median":-3.568226,"eighty":15.739397,"marketCap":2102867237},{"date":"2025-07-03","current":17.061675,"twenty":-10.162337,"median":-3.549185,"eighty":15.841236,"marketCap":2166832781},{"date":"2025-07-08","current":16.683926,"twenty":-10.162337,"median":-3.544901,"eighty":15.9278,"marketCap":2118858623}],"updateTime":1752122376627}}}